Spevigo (spesolimab-sbzo)

Buy Spevigo (spesolimab-sbzo) online – Spevigo (spesolimab-sbzo) for sale

What is Spevigo (spesolimab-sbzo) for?

Spevigo (spesolimab-sbzo) is an antibody that blocks the activation of the interleukin 36 receptor (IL-36R). The interleukin 36 signaling pathway, part of the immune system, has been shown to be involved in causing generalized pustular psoriasis (GPP) flares.

GPP is a rare and extreme form of psoriasis characterized by repeated episodes in which large areas of skin become red and inflamed and develop small pustules. It is caused by changes in the IL36RN gene. Spevigo works by blocking the activation of the interleukin-36 receptor (IL-36R), a key part of a signaling pathway within the immune system shown to be involved in the cause of GPP.

Spevigo is administered as a single dose by intravenous infusion over 90 minutes.

What is the approval status of Spevigo (spesolimab-sbzo)?

Spevigo was approved by the US Food and Drug Administration (FDA) on 1 September 2022 as a treatment option for generalized pustular psoriasis (GPP) flares in adults. Read more about it here.

The prescribing information for Spevigo (spesolimab-sbzo) can be consulted here.